Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer
August 14 2023 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that
Gülsen Kama will serve as its next Chief Financial Officer
(CFO), effective September 11, 2023. Christopher Stewart, who held
the position of CFO since September 2020, will stay on during the
transition and then move into an advisory role.
Ms. Kama has an extensive background in business planning
and execution, especially in operating environments that demand
rigorous management of expenses to enable profitable growth. She
was most recently Chief Financial Officer at Northern Data AG,
where she created and implemented a global finance organization to
enable strong growth. Prior to Northern Data AG, Ms. Kama was
Chief Financial Officer, East Region and Healthcare IT at Quest
Diagnostics, Quest’s largest region, where she drove market
expansion and operational efficiencies. Before Quest, Ms. Kama
established an impressive track record of transformative and
growth-oriented leadership across a diverse range of
multibillion-dollar organizations, including FedEx, United
Airlines, A&P, and AIG, where she held senior leadership roles
in strategic planning, financial planning and analysis, capital
planning and corporate strategy.
“I am pleased to welcome Gülsen to Bionano. We believe the
combination of her track record managing financial strategy at
global businesses, including Quest Diagnostics and United Airlines,
combined with her experience helping scale startup Northern Data,
make her well-suited to help Bionano continue transforming
cytogenetics into a streamlined workflow in healthcare while
charting a course toward profitability. Gülsen has decades of
capital management experience at complex companies, where she
helped improve efficiency and implemented cost controls, resulting
in higher returns to shareholders. All of us on the senior
leadership team are really looking forward to partnering with
Gülsen as she helps propel us to reach new heights. We also extend
our gratitude to Chris Stewart for his leadership in helping us
transition out of the pandemic and build our growing business,”
commented Erik Holmlin, PhD, president and chief executive
officer of Bionano.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information, visit www.bionano.com, www.bionanolaboratories.com or
www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “plan,” “potential,” “will” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations, including
any potential benefits that may be realized as a result of new
members of management. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of geopolitical and macroeconomic developments, such as
recent and potential future bank failures, the ongoing
Ukraine-Russian conflict, and related sanctions, and any global
pandemics, on our business and the global economy; execution of our
stated strategies and plans[delete extra space]; general market
conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts and our ability to
continue as a “going concern”; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2022
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jul 2023 to Jul 2024